StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Tirbanibulin

HCID 23635314
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
897016-82-9
Standard-SMILES
O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1
InChIKey
HUNGUWOZPQBXGX-UHFFFAOYSA-N
Summenformel
C26H29N3O3
Durchschnittliche Molmasse
431,5 g/mol
Monoisotopische Masse
431,2208918

Überblick

Tirbanibulin is a member of the class of pyridines that is pyridine substituted by 2-(benzylamino)-2-oxoethyl and 4-[2-(morpholin-4-yl)ethoxy]phenyl groups at positions 2 and 5, respectively. It is a dual inhibitor of Src kinase and tubulin and approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It has a role as an antineoplastic agent, a microtubule-destabilising agent, an apoptosis inducer and an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor. It is a secondary carboxamide, a member of pyridines, an aromatic ether and a member of morpholines.

Namen und Bezeichner

Bevorzugter Name
Tirbanibulin
IUPAC
N-benzyl-2-[5-[4-(2-morpholin-4-ylethoxy)phenyl]-2-pyridinyl]acetamide
Englischer Name
Tirbanibulin
Summenformel
C26H29N3O3
Molmasse
431.53

Namen und Synonyme

Tirbanibulin897016-82-9KX2-391KX-01N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetamideKlisyriKX01KX-2-391tirbanibulinatirbanibulineKX-23914V9848RS5G
Weitere Namen anzeigen
KX 01CS-234KX-O1)KX2-391 (KX01)KX2-391 USP/EP/BPTirbanibulin, KX2-391KX2-391(Tirbanibulin)KX2 391Tirbanibulin, 10 mM in DMSO
KX2391N-benzyl-2-(5-{4-[2-(morpholin-4-yl)ethoxy]phenyl}pyridin-2-yl)acetamideDTXSID302378622-Pyridineacetamide, 5-(4-(2-(4-morpholinyl)ethoxy)phenyl)-n-(phenylmethyl)-tirbanibulinumN-benzyl-2-(5-(4-(2-(morpholin-4-yl)ethoxy)phenyl)pyridin-2-yl)acetamide2-(5-(4-(2-morpholin-4-ylethoxy)phenyl)pyridin-2-yl)-N-(phenylmethyl)acetamide2-[5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-yl]-N-(phenylmethyl)acetamide

Datenbank-Bezeichner

CAS
897016-82-9
PubChem CID
23635314
DTXSID
DTXSID30237862
ChEMBL

Eigenschaften

Berechnete Struktureigenschaften

XLogP
2,9
Polarare Oberfläche (TPSA)
63,7 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
5
Frei drehbare Bindungen
9
Schwere Atome
32
Formalladung
0
Komplexität
540

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
Human Drugs · 4 Einträge

Breast Feeding; Lactation; Milk, Human; Antineoplastic Agents; Dermatologic Agents

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Physikochemische Eigenschaften

Siedepunkt
680.9 · 680.9±55.0 °C(Predicted)
Dichte
1.169 · 1.169
storage temp.
-20 °C · Store at -20°C
Löslichkeit
2 O; · insoluble in H2O; ≥121 mg/mL in DMSO; ≥2.44 mg/mL in EtOH with gentle warming and ultrasonic
Aggregatzustand
Powder
pka
14.73 · 14.73±0.46(Predicted)
Farbe
White to off-white
InChI
InChI=1S/C26H29N3O3/c30-26(28-19-21-4-2-1-3-5-21)18-24-9-6-23(20-27-24)22-7-10-25(11-8-22)32-17-14-29-12-15-31-16-13-29/h1-11,20H,12-19H2,(H,28,30)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS ClassificationNot Classified

Gefahrenhinweise

Hazard Classes and CategoriesNot Classified

Toxikologische Informationen

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

Alarmwort
Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H315

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

D - Dermatologicals

QD - Dermatologicals

Protein BindingTirbanibulin is 88% bound to plasma proteins and the extent of plasma protein binding is independent of drug concentrations in the range of 0.01 to 10 µg/mL.
Pharmacodynamics · 1 Eintrag

In clinical trials composed comprising patients with actinic keratosis of the face or scalp, tirbanibulin promoted complete clearance of actinic keratosis lesions at day 57 in treated areas in 44-54% of patients compared to 5-13% of patients who received the placebo. Actinic keratosis is a chronic, pre-malignant condition characterized by lesions and proliferation of neoplastic keratinocytes. Tirbanibulin mediates an anti-proliferative effect by inhibiting tubulin polymerization and Src kinase signalling. Tirbanibulin inhibited primary tumour growth and metastasis in many preclinical animal models of cancer. In human triple-negative breast cancer, or estrogen receptor (ER)/progesterone receptor (PR)/human epidermal growth factor receptor 2 (HER2)-negative tumour, xenografts, tirbanibulin suppressed tumour growth and metastasis. Tirbanibulin was also shown to restore functional ERα expression in ERα-negative breast tumours. Tirbanibulin promoted synergistic tumour growth inhibition of breast cancer cell lines when used in combination with tamoxifen and paclitaxel. In a clinical trial comprising patients with advanced solid tumours, dose-limiting toxicities of tirbanibulin included elevated liver transaminases, neutropenia and fatigue.

Mechanism of Action · 1 Eintrag

Src tyrosine kinases regulate normal cell growth: the expression of Src kinase is upregulated during the normal hair cycle during the proliferative anagen phase. Additionally, Src tyrosine kinases act as key modulators of cancer cell proliferation, survival, angiogenesis, migration, invasion and metastasis. Src is frequently upregulated in various epithelial tumours including colon, breast and pancreas compared with the adjacent normal tissues. The expression and activity of Src are also enhanced in human actinic keratosis, which is characterized by hyperproliferative premalignant skin lesions. The pathogenesis of actinic keratosis commonly involves skin inflammation, oxidative stress, immunosuppression, impaired apoptosis, mutagenesis, dysregulation of keratinocyte growth and proliferation, and tissue remodelling. _In vitro_ studies suggest that Src plays a predominant role in the early stages of human skin tumour development, rather than at later stages of tumour progression. The exact mechanism of tirbanibulin as a topical treatment of actinic keratosis has not been fully elucidated; however, it mainly works by inhibiting fast proliferating cells. Tirbanibulin is a non-ATP competitive Src kinase inhibitor and tubulin polymerization inhibitor. It binds to the peptide substrate binding site of Src, a primary target of tirbanibulin, and blocking its downstream signalling pathways that promote cancer cell migration, proliferation, and survival. Tublin is responsible for cell migration, protein transport, and mitosis: tibranibulin directly binds to the colchicine-binding site of beta-tubulin and causes induces tubulin depolymerization. It is also hypothesized that inhibition of Src can also contribute to the inhibitory effects on microtubule polymerization. At low nanomolar concentrations, tirbanibulin induces G2/M phase cell cycle arrest in a reversible and dose-dependent manner. By inhibiting microtubule polymerization, tirbanibulin also induces mitotic catastrophe.

Zugehörige Reaktionen

131
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 108958
HRID 108958als Edukt
Reaktionsgleichung von HRID 160909
HRID 160909als Produktals Edukt
Reaktionsgleichung von HRID 179281
HRID 179281als Produkt
Reaktionsgleichung von HRID 182311
HRID 182311als Edukt
Reaktionsgleichung von HRID 200028
HRID 200028als Edukt
Reaktionsgleichung von HRID 213143
HRID 213143als Produkt
Reaktionsgleichung von HRID 303192
HRID 303192als Produkt
Reaktionsgleichung von HRID 403217
HRID 403217als Produkt
ZurückSeite 1 von 17

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
CHEMBL571546
ChEBI
CHEBI:231702
UNII
4V9848RS5G
EC Number
854-810-1
InChIKey
HUNGUWOZPQBXGX-UHFFFAOYSA-N
SMILES
C1(CC(NCC2=CC=CC=C2)=O)=NC=C(C2=CC=C(OCCN3CCOCC3)C=C2)C=C1
Biological Half-LifeThe half-life is about 4 hours.
Metabolism/Metabolites · 1 Eintrag

_In vitro_, tirbanibulin is mainly metabolized by CYP3A4, and to a lesser extent, CYP2C8. In adult subjects with actinic keratosis, detected metabolites were KX2-5036 and KX2-5163, which were pharmacologically inactive metabolites with the highest plasma concentrations of 0.09 ng/mL and 0.12 ng/mL, respectively.

FDA Pharmacological Classification · 6 Einträge

4V9848RS5G

TIRBANIBULIN

Physiologic Effects [PE] - Microtubule Inhibition

Established Pharmacologic Class [EPC] - Microtubule Inhibitor

Tirbanibulin is a Microtubule Inhibitor. The physiologic effect of tirbanibulin is by means of Microtubule Inhibition.

TIRBANIBULIN

MeSH Pharmacological ClassificationCompounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
Absorption, Distribution and Excretion · 4 Einträge

Tirbanibulin demonstrates good oral bioavailability. Following topical administration of doses ranging from 54 to 295 mg on the face or scalp, the steady-state concentration of tirbanibulin was achieved by 72 hours. At five days following initial administration, the mean Cmax was 0.34±0.30 ng/mL in subjects who received topical treatment on the face and 0.18±0.10 ng/mL in subjects who received topical treatment on the scalp. The mean AUC24 was 5.0±3.9 h x ng/mL in subjects who received topical treatment on the face and 3.2±1.9 h x ng/mL in subjects who received topical treatment on the scalp. The median Tmax was about seven hours.

There is limited information on the route of elimination of tirbanibulin.

There is limited information on the volume of distribution of tirbanibulin. In mouse HT29 xenograft studies, the tissue to plasma ration of tirbanibulin was 1.52.

There is limited information on the clearance rate of tirbanibulin.

Anwendungen

VerwendenKX2-391 is a Src Inhibitor with efficacy against certain hepatic and leukemia cell lines.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

Methyl 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetateBenzylamin